RbAp48 transgenic mice for drug discovery in age-related memory decline

US9387263B2 · kind B2 · utility

Assignee

• The Trustees of Columbia University in the City of New York · US

Inventors

• Scott A. Small · Millerton, US
• Ilias Pavlopoulos · New York, US
• Eric R. Kandel · Yonkers, US

Key dates

• Filing date: Aug 2, 2012
• Grant date: Jul 12, 2016
• Expiry date: Sep 3, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2830/003
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described is a transgenic mouse with two transgenes, each of which transgene comprises a DNA sequence encoding a dominant negative form of RbAp48 protein, wherein the expression of the dominant negative form of RbAp48 is spatially restricted to the forebrain by a CaM Kinase IIa promoter and wherein the expression of the dominant negative form of RbAp48 is controlled by tetracycline-controlled transcriptional activation. Also provided are methods for evaluating in the transgenic mouse the potential therapeutic effect of an agent for slowing, inhibiting or preventing age-related memory decline in a mammalian subject.